Omzo vs Enhance MD: Clinician-Guided Care vs Low Intro Pricing
Compare Omzo vs Enhance MD for GLP-1 weight-loss care: Omzo emphasizes clinician-guided, personalized compounded semaglutide starting at $179 while Enhance MD emphasizes low introductory pricing with semaglutide from $49 first month and flat-rate ongoing pricing. Quick verdict: Choose Omzo if you want clinician-reviewed programs and the option for provider prescriptions; choose Enhance MD if your priority is the lowest first-month cost and predictable flat-rate pricing.
Explore Omzo clinician-guided plans
Key difference 1: Pricing structure and entry cost
Enhance MD advertises semaglutide from $49 for the first month and tirzepatide from $99 for the first month. Enhance MD highlights flat-rate pricing that stays the same at every dose after the introductory period, which it presents as a way to avoid fee escalation during titration. Omzo lists semaglutide starting at $179 and tirzepatide starting at $279 as part of clinician-guided plans. The supplied evidence shows Enhance MD has a substantially lower first-month price point than Omzo.
Key difference 2: Clinician model and prescription approach
Both platforms use licensed clinicians to determine medical appropriateness. Omzo presents clinician-guided plans reviewed by licensed U.S. providers and notes clinical services are provided by third party networks of U.S.-licensed clinicians who determine eligibility and make final prescribing decisions. Enhance MD is described as a licensed telehealth platform with clinician-directed compounds and a large treated patient base. Omzo also states providers may write prescriptions for branded medications but Omzo does not sell or ship branded products; if prescribed, patients fill those prescriptions themselves.
See Enhance MD pricing and plans
Key difference 3: Compounded medication status and regulatory notes
Both sources include the regulatory qualification that compounded medications offered are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Omzo explicitly describes a Compounded Medication Program produced by state-licensed sterile compounding pharmacies and repeats that compounded drugs are not FDA-approved. Enhance MD also states that its clinician-directed compounds are compounded and not FDA-approved finished products. These qualifications appear in both provider descriptions and should be considered when comparing options.
Key difference 4: Transparency on long term pricing and volume
Enhance MD emphasizes flat-rate pricing that stays the same at every dose and notes a 10,000+ patient treatment volume in its marketing. Omzo emphasizes clinician-reviewed personalized plans and lists starting prices but warns that pricing, eligibility, pharmacy, state coverage and renewal terms may change. The supplied evidence shows Enhance MD stresses predictable dose-independent pricing, while Omzo stresses personalized clinical oversight with fees presented as starting rates.
Comparison table at a glance
| Criteria | Omzo | Enhance MD |
|---|---|---|
| Starting semaglutide price | $179 starting | $49 first month |
| Tirzepatide starting price | $279 starting | $99 first month |
| Pricing model | Clinician-guided plan fees listed as starting prices | Introductory low price then flat-rate ongoing pricing |
| Medication type offered | Compounded semaglutide and tirzepatide; providers may prescribe branded medications but Omzo does not sell them | Compounded semaglutide and tirzepatide on platform; no branded products sold |
| Regulatory note | Compounded medications not FDA-approved | Compounded medications not FDA-approved |
| Clinical oversight | Licensed U.S. providers in third party networks review plans | Clinician-directed review; reported 10,000+ patients treated |
Other practical differences to weigh
Omzo notes medication costs can be included in fees collected and that Omzo pays pharmacies used by the platform, while Omzo also clarifies that if a clinician prescribes a branded medication the patient is responsible for filling it at a pharmacy. Enhance MD emphasizes no dose escalation fees and presents introductory savings and flat-rate ongoing pricing, and also references metabolic lab testing every six months in its published materials. Where the sources are silent, no further claims are made.
Safety and expectations
Both providers state that compounded medications are not FDA-approved and that treatment is available only when a licensed clinician determines it is medically appropriate. Omzo explicitly says individual results may vary and that weight loss is not guaranteed. Enhance MD notes its compounds use the same active ingredients as branded versions but are compounded products.
Conclusion: Choose based on oversight or entry price
Omzo vs Enhance MD comes down to priorities. Omzo focuses on clinician-guided, personalized plans with starting prices like $179 for semaglutide and clarifies provider options for prescribing branded medications that patients must fill separately. Enhance MD offers the lowest first-month prices among the two sources and flat-rate ongoing pricing to avoid dose-based escalation, with semaglutide from $49 first month and tirzepatide from $99 first month. Both offer compounded medications that are not FDA-approved and both use licensed clinicians for review.
Choose Omzo if…
You prioritize clinician-guided, personalized GLP-1 plans reviewed by licensed U.S. providers and the option that a provider may prescribe a branded medication which you would then fill at a pharmacy.
Choose Enhance MD if…
You prioritize the lowest first-month cost and predictable flat-rate pricing that stays the same at every dose, plus access to both semaglutide and tirzepatide with a large treated patient base.